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ABSTRACT: 
Limbrel  (flavocoxid)  is  marketed  as  an  FDA-regulated  medical  food  for  the  clinical  dietary 
management  of  osteoarthritis  (OA)  to  be  used  under  physician  supervision.  Flavocoxid  is 
composed  of  a  >90%  mixture  of  baicalin  and  catechin  and  represents  a  non-targeted  anti-
inflammatory which works differently than non-steroidal anti-inflammatory drugs (NSAIDs) that 
bind to and only inhibit the cyclooxygenase moieties of COX-1 and COX-2. Flavocoxid binds to 
and  weakly  modulates  the  peroxidase  activity  of  the  COX  enzymes  permitting  low  level 
expression of prostaglandins (PGs), prostacyclin (PGI2) and thromboxane (TxA2). In addition, 
flavocoxid weakly inhibits phospholipase A2 (PLA2) and 5-lipoxygenase (5-LOX) as well as 
increases  IBα  and  prevents  nuclear  factor  kappa  B  (NFB)  activation/induction  of 
inflammatory genes such as tumor necrosis factor-alpha (TNFα), interleukin-1β (IL-1 β), IL-6, 
COX-2,  inducible  nitric  oxide  synthase  (iNOS)  and  5-LOX.    In  clinical  studies,  flavocoxid 
shows  equivalent  efficacy  to  naproxen  with  statistically  fewer  renal  (edema)  and  upper 
gastrointestinal (GI) side effects, does not affect platelet function and bleeding times, does not 
change international normalized ratio (INR) in warfarinized patients, is well-tolerated in patients 
with  previous  NSAID-induced  GI  side  effects,  and  decreases  or  eliminates  the  use  of 
gastroprotective medications in patients who previously required them to tolerate NSAIDs. With 
its broad, non-targeted and multiple weak activities which result in fewer side effects compared 
to NSAIDs, flavocoxid represents a different way managing OA by working on the underlying 
and multiple causes of cartilage degradation as well as joint inflammation.  
 
Keywords: Flavocoxid, Limbrel, osteoarthritis, inflammatory pathways, and medical foods 
 
 
REVIEW: 
Second only to  beta-lactam drugs,  NSAIDs,  as a  class,  are the leading  cause of acute drug 
reactions and drug-induced side effects [1]. Although multiple treatment modalities are used to Functional Foods in Health and Disease 2012, 2(11):379-413  Page 380 of 413 
manage OA, including physical therapy, analgesics, intra-articular injections of corticosteroids or 
hyaluronate  preparations  and  surgical  interventions,  NSAIDs  remain  the  mainstay  of  most 
chemical therapeutic regimens. While effective for relieving pain, these drugs often lead to GI, 
renal, hepatic, blood clotting and cardiovascular toxicities. Most of these adverse effects are 
caused by imbalances in arachidonic acid (AA) metabolism due to specific inhibition of COX-1, 
COX-2  and  5-LOX  changing  the  eicosanoid  generation  profile  which  serve  important 
physiologic functions  both  within and beyond articular structures  [2, 3]. Even with multiple 
NSAIDs and modalities for treatment of OA, this chronic and debilitating disease remains a 
serious  problem  affecting  25-40  million  people  in  the  United  States  [4-6]  with  similar  data 
reported in other countries [7].  Epidemiological studies show that Asian and Mediterranean 
countries have a substantially lower incidence of knee OA, suggesting a role for nutrition in the 
etiology of the disease [8]. For example, Asian and Mediterranean countries consume an equal 
proportion of inflammatory omega-6 (precursors to AA production) to anti-inflammatory omega-
3 fatty acids compared to Americans who consume about a 20-30:1 ratio of these molecules [9]. 
Another way to manage the effects of imbalances in nutrition which result in chronic diseases is 
through the administration of medical foods. 
 
The  Medical  Foods  Category.  Medical  foods,  a  therapeutic  category  unique  to  the  US,  are 
ideally  positioned  to  provide  the  clinical  dietary  management  of  chronic  diseases  like  OA. 
Unlike drugs, medical foods are not FDA approved, but are subject to a set of governing statutes 
and regulations specific to this class of therapeutics. In addition, despite a similar name to dietary 
supplements, medical foods have strict requirements for safety, labeling and use (see below). 
Medical foods are required to support all claims with good laboratory and clinical science. The 
category of medical foods was created in an addendum to the Orphan Drug Act of 1988 [10]. 
Prior to this law, these products were regulated as drugs. The definition of a medical food was 
restated in the FDA’s Final Rule on Mandatory Nutritional Labeling, 1993 [11]. Specifically, a 
product classified as a medical food must meet the following requirements, among others: 
 It is composed of specially formulated and processed nutrients (as opposed to naturally 
occurring foodstuffs used in their natural state or extractions of plants) at concentrations which 
cannot be attained by dietary modification. These nutrients must provide for a distinct nutritional 
requirement for disease management. 
 It must be consumed or administered enterally, either by ingestion or intragastric tube. 
 It provides nutritional support specifically modified for the management of the unique 
nutrient  needs  that  are  associated  with  the  specific  disease  or  condition,  as  determined  by 
medical evaluation. 
 It is intended to be used under medical supervision (i.e., by prescription, provided from a 
physician’s office or in a clinical setting such as a hospital). 
 It  is  intended  only  for  a  subject  receiving  active  and  ongoing  medical  supervision 
wherein  the subject  requires  medical  care on  a recurring basis  for a  chronic condition(s) or 
disease(s). 
 It is composed of ingredients designated as generally recognized as safe (GRAS). For an 
ingredient to achieve GRAS status requires not only a technical demonstration of non-toxicity, Functional Foods in Health and Disease 2012, 2(11):379-413  Page 381 of 413 
but also an agreement of that safety after extensive peer review by an independent panel of 
experts in the field. 
 It is based on recognized scientific principles (i.e., preclinical and clinical science). 
 It must list its molecular ingredients in descending order on the label and provide clear 
directions to assure their safe use under physician supervision. 
Based on this strict definition and regulatory structure, medical foods represent an option 
which physicians may choose for their patients  to provide dietary management of a chronic 
condition or disease under physician supervision.  
 
Distinct Nutritional Requirements in Osteoarthritis.  
The prerequisite that there be a “distinct nutritional requirement” to manage OA with a medical 
food has evolved over many years as scientists and clinicians understand more about nutrition 
and  joint  damage.  The  role  of  nutrition  in  joint  disease  is  complex  and  may  be  linked  to 
nutritional deficiencies early as well as later in life [12]. The excess intake of inflammatory 
omega-6 fatty acids and the lack of natural anti-inflammatory compounds in the diet to mitigate 
this consumption in the US diet, for example, is part of the etiology of the growing incidence of 
OA. This is commensurate with a concept known as dietary-genetic discordance [13]. Briefly, 
this refers to the fact that our genetic makeup has not changed significantly in the 50,000 years, 
or so, since the days of early hominids. Genetically, our metabolic pathways are programmed to 
account for diets that consisted primarily of fruits, berries, vegetables, fish and lean meat which 
have high levels of anti-inflammatory and antioxidant molecules such as flavonoids and other 
polyphenols and an omega-6/omega-3 ratio of approximately 2:1. With the advent of agriculture 
and  animal  husbandry  10,000  years  ago  our  diets  started  to  become  discordant  with  our 
metabolic genetic constitution and this discordance was further and dramatically altered with the 
advent of highly processed foods around the beginning of the twentieth century. The net result is 
that we now consume a diet low in natural antioxidants such as flavonoids and high in omega-6 
fatty acids for which we do not possess appropriate metabolic pathways. 
  Arachidonic acid is derived from the dietary intake of omega-6 fatty acids (i.e., linoleic 
acid) as well as AA itself. Omega-6 fatty acids are processed by sequential desaturation and 
elongation [14].  Fatty acid imbalances are commonly seen in patients with chronic inflammatory 
conditions  such  as  arthritis.  Osteoarthritic  joints  show  increased  levels  of  lipid  and  AA 
accumulation which correlate with histological severity in joint disease [15, 16].  Total fatty acid 
levels  in  subchondral  bone  have  also  been  shown  to  be  50%-90%  higher  in  OA  patients 
compared to controls or to osteoporotic individuals [17]. Similarly, bone marrow lesions in OA 
have been found to contain high levels of mono-, poly- and omega-6 polyunsaturated fatty acids 
compared to non-diseased control groups [18]. Dietary lipids have also been shown to modify 
the fatty acid composition of cartilage [19]. In addition, clinical studies have shown a strong 
linkage between metabolic defects in fatty acid metabolism or an overabundance of fatty acids 
that lead to OA [20]. A recent study of over 500 patients who had or were at high risk for 
developing  OA  showed a  clear association between knee synovitis  as  assessed by MRI  and 
omega-6 fatty acid intake [21]. It is unclear whether increased intake of omega-3 fatty acids can 
reverse the effect  of AA in  treating OA in  humans. Clinical  trials  assessing the  efficacy of 
omega-3 fatty acids in human OA to date have reached conflicting conclusions and formulations Functional Foods in Health and Disease 2012, 2(11):379-413  Page 382 of 413 
tested thus far tend to contain mixtures of omega-3 fatty acids with other compounds [22, 23]. 
Therefore, it is not known if AA presence in OA joints can be decreased by dietary intervention 
with omega-3 administration. It is clear, however, that other dietary molecules which are lacking 
in the US diet can be supplied at high levels to manage the metabolism of AA overabundance 
associated with OA. 
Dietary flavonoid intake has been shown to mitigate the occurrence and severity of many 
chronic diseases, especially those with inflammation as part of their etiology [24-26]. Americans 
and Northern Europeans consume fewer natural anti-inflammatory and antioxidant molecules 
compared to  Asian and Mediterranean countries  [24, 27-31]. These differences  appear to be 
largely  due  to  food  processing  differences  which  destroy  flavonoid  compounds  and  to  food 
preferences [28, 32]. In addition, there is an inverse relationship between socioeconomic level 
and flavonoid as well as antioxidant intake in the US [33, 34]. 
Recent  experiments  in  preclinical  transgenic  male  mice  which  can  express  human  C-
reactive  protein  (CRP)  show  that  a  high-fat  diet  significantly  induces  higher  OA  grades  in 
comparison to mice on normal chow [35]. There was no correlation between the severity of OA 
observed and body weight suggesting that a low-grade metabolically-based inflammatory state 
and not obesity or mechanical load leads to OA severity. In humans, flavonoid intake has also 
been shown to be inversely related to CRP levels suggestive of systemic inflammation in males 
and females of all ages [36-39]. Flavonoids have been shown to affect arthritis in both animals 
and humans. 
Numerous models of experimental arthritis which induce high levels of reactive oxygen 
species (ROS) have shown that flavonoids from a variety of sources slow the progression and 
mitigate  the  effects  of  inflammation  in  rheumatoid  arthritis  (RA)  [40-42].  Flavonoids  like 
nobiletin  from  citrus,  for  example,  decrease  the  production  of  aggrecanases  which  directly 
degrade cartilage in collagen-induced arthritis (CIA) models [43]. It has also been shown that 
initial  joint  injury  which  is  associated  with  eventual  joint  degradation  in  OA  is  related  to 
increases  in  ROS.  When  articular  cartilage  chondrocytes  were  taken  from  young  adults  and 
exposed to mechanical and oxidative stress, there was increased release of ROS and induction of 
chondrocyte senescence [44]. Animal models have also shown that compression injury increases 
ROS  levels  which  induce  apoptosis  and  maturation  of  chondrocytes  [45].  Finally,  in 
experimental models of articular cartilage stress, addition of antioxidants mitigated chondrocyte 
death  [46,  47].  These  observations  suggest  that  joint  injury  increases  ROS  production, 
chondrocyte  senescence  and  death  and  that  these  effects  are  mitigated  by  the  addition  of 
antioxidants. Similar findings have also been demonstrated in a number of human studies. It is 
clear that initial traumatic injury is associated with a change in joint tissue and an increased 
generation of ROS which eventually leads to OA. 
Using  food  intake  questionnaires,  the  Framingham  Study  demonstrated  an  association 
between vitamin C, beta carotene and vitamin E intake with the incidence and progression of OA 
compared to a panel of non-antioxidant vitamins [48]. High intakes of vitamin C were associated 
with a reduced risk of developing knee pain suggesting a decrease in the progression of OA [48]. 
Baker et al [49], in a longitudinal study of 324 participants followed for 30 months who were 
evaluated  by  food  questionnaire,  showed  that  individuals  who  consumed  either  200  mg/day 
(men) or 150 mg/day (women) of vitamin C had significant reduction in knee pain.  In addition, Functional Foods in Health and Disease 2012, 2(11):379-413  Page 383 of 413 
293 healthy patients without knee pain or injury were assessed for intake of antioxidant vitamins 
and food sources including those containing carotenoids by a food frequency questionnaire at 
baseline and 10 years later and compared with measurements of bone area, cartilage defects and 
bone marrow lesions assessed by MRI [50]. High vitamin C intake was associated with a reduced 
risk of bone marrow lesions and reduced tibial plateau bone area. There was also an inverse 
association between fruit intake and bone area as well as bone marrow lesions. It was also found 
that  intake  of  the  carotenoids  lutein  and  zeaxanthin  reduced  cartilage  defects  while  β-
cryptoxanthin was inversely associated with reduction of tibial plateau bone area. These results 
suggest  the  need  for  antioxidants  to  modulate  joint  damage.  Indeed,  multiple  investigators 
suggest that OA can be managed by the addition of flavonoids and antioxidants to treatment 
regimens  [51-54].    The  accumulated  evidence  of  all  of  these  studies  strongly  supports  the 
“distinct  dietary  requirement”  of  antioxidants  in  the  form  of  vitamins  and  polyphenolic 
compounds such as flavonoids and carotenoids for the management of OA. With this in mind, 
flavocoxid was specially formulated to provide for these distinct dietary requirements. 
 
Characterization of Flavocoxid’s Mechanism of Action:  
Baicalin  and  catechin,  the  constituents  of  flavocoxid,  were  isolated  by  high  throughput 
cyclooxygenase  (using  COX-1  and  COX-2  peroxidase  inhibition  screening)  and  5-LOX 
inhibition screening of over 5000 plant extracts [55]. As a medical food, flavocoxid is required 
by  FDA  regulations  to  be  produced  under  food  good  manufacturing  practices  (GMPs). 
Flavocoxid, however, is manufactured using pharmaceutical standards which involves setting 
specific ingredient ranges for each active entity, testing and setting stability for shelf-life of the 
product as well as testing for contaminating molecules such as pesticide [56] and liver damaging 
aflatoxins [57] which may be present due to growing conditions. This review represents a current 
summary of flavocoxid’s mechanism of action, preclinical and clinical safety and efficacy data, 
and compares the clinical research of other nutritional molecules for the management of OA.  
 
Flavocoxid  Arachidonic  Acid  Mechanism.  Arachidonic  acid  is  derived  from  both  PLA2 
conversion of cell membrane phospholipids  and dietary consumption of omega-6 fatty acids 
[58]. This fatty acid is a necessary substrate for a variety of physiological processes, including 
those involving cell membrane composition, platelet function, inflammation and tissue function 
and  repair.  In  OA  and  many  other  diseases,  COX-1,  COX-2  and  5-LOX  enzymes  produce 
effectors of pain and inflammation which are derived from AA.  All three enzymes play a key 
role in the metabolism of AA to inflammatory fatty acids (eicosanoids) which contribute to the 
deterioration of cartilage (Figure 1).  
During the metabolism of AA by the COX enzymes, two oxygen molecules are added by a 
cyclooyxgenase activity to AA to yield prostaglandin G2 (PGG2) [59] (Figure 2). The transient, 
short-lived PGG2 intermediate is then converted to prostaglandin H2 (PGH2) by a peroxidase 
activity  via  a  reduction  reaction.  A  variety  of  cellular  and  tissue  specific  isomerases  and 
synthases then convert PGH2 to various PGs, PGI2 and TxA2 (Figure 2). 
It was originally thought that COX-1 and COX-2 metabolic differences in AA conversion 
were due to compartmentalization of each enzyme on different structural components within the 
cell. Both  enzymes, however, are equally present  on the endoplasmic  reticulum and nuclear Functional Foods in Health and Disease 2012, 2(11):379-413  Page 384 of 413 
membranes [60]. The cyclooxygenase activity of COX-2 requires ~10-fold less hydroperoxide 
for activation compared to COX-1 and metabolizes AA at a greater rate [61]. Both COX-1 and 
COX-2 produce maintenance levels of the vasodilator PGI2 from human endothelial cells [62]. 
 
 
Figure 1. Pathways of origin and processing of arachidonic acid (AA) to eicosanoid fatty acid 
metabolites through the COX-1/-2 cyclooxygenase and peroxidase activities to prostaglandin E2 
(PGE2),  prostacyclin  (PGI2)  and  thromboxane  (TxA2),  through  the  5-LOX  enzyme  to  the 
leukotrienes LTB4, LTC4 and LTD4 and the chemical change of AA to oxidized lipids by ROS. 
 
 
Figure 2. Processing of arachidonic acid (AA) by the COX enzyme activities of cyclooxygenase 
to  prostaglandin  G2  (PGG2)  and  peroxidase  to  prostaglandin  H2  (PGH2)  to  eicosanoid 
metabolites of thromboxane (TxA2) as well as prostaglandin E2 (PGE2) and prostacyclin (PGI2) 
 
Prostacyclin  is,  however,  produced  at  a  faster  rate  by  COX-2  compared  to  COX-1  [63].  In 
addition,  each  isozyme  is  coupled  to  specific  synthases  and/or  isomerases  for  the  final 
conversion of the PGH2 intermediate from each COX enzyme in many cell types and platelets 
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[58]. For example, PGI2 is specifically produced in the cardiovascular system through coupling 
of COX-2 with PGI2 synthase, while TxA2 production is coupled in platelets to COX-1 and TxA2 
synthase. 
The initial testing of the mechanism of action (MOA) for flavocoxid focused on the effect 
of the baicalin and catechin mixture on inhibition of COX-1 and COX-2 peroxidase activities 
and the 5-LOX enzyme [64]. The initial analysis showed a balanced, weak inhibition of the 
peroxidase activities in the COX enzymes (15 µg/ml) and of 5-LOX (29 µg/ml). Flavocoxid also 
reduced PGE2 in cultures of HOSC cells, a human osteosarcoma cell line expressing COX-2, and 
leukotriene (LTB4) production in cultures of THP-1 cells, a monocyte cell line that expresses 
COX-1, COX-2, and 5-LOX.  
In a recently published paper, oxygen sensing assays for the cyclooxygenase activity and 
peroxidase inhibition were used to separate the two activities of the COX enzymes comparing 
indomethacin  (a  strong  COX-1  cyclooxygenase  inhibitor)  and  NS-398  (a  strong  COX-2 
cyclooxygenase inhibitor) to flavocoxid  [65]. The assays revealed a  relatively balanced anti-
peroxidase activity of flavocoxid on COX-1 (IC50=12.3 μg/ml) and COX-2 (IC50= 11.3 μg/ml) 
and  only  a  weak  COX-1  cyclooxygenase  activity  (IC50=25  µg/ml).  Flavocoxid  gave  no 
detectable COX-2 cyclooxygenase inhibition in this oxygen sensing assay. Indomethacin yielded 
a IC50 of 0.012 µg/ml, 2000-fold stronger than flavocoxid, and NS-398 gave an IC50 of 0.095 
µg/ml  in  the  oxygen  sensing  assay.  Flavocoxid  was  the  only  inhibitor  of  5-LOX  enzyme 
(IC50=110  µg/ml)  compared  to  rofecoxib,  valdecoxib,  celecoxib,  meloxicam,  diclofenac, 
ibuprofen, naproxen and aspirin, all of which showed no inhibitory activity.  
Though NSAIDs bind only to the cyclooxygenase site in the COX enzymes preventing the 
conversion of AA to PGG2 thus stopping the process of eicosanoid generation, it is hypothesized 
that redundant cellular peroxidase activities can convert PGG2 to PGH2 to eicosanoid products 
via alternate pathways in target organs. This hypothesis is supported in humans administered 500 
mg flavocoxid BID for 2 weeks in a platelet function study in which  TxA2 production was 
unaffected [66]. Traditional NSAIDs are known to decrease the production of TxA2 from the 
COX-1 enzyme [67]. The anti-5-LOX activity of flavocoxid may also prevent a putative shunt of 
AA metabolism toward leukotriene (LT) production which NSAIDs (including selective COX-2 
inhibitors)  have  been  shown  to  promote  based  on  both  preclinical  and  clinical  results  [68]. 
Finally, flavocoxid demonstrated a weak anti-PLA2 activity (IC50=60 µg/ml) in macrophage 
cultures. By broadly modulating the production of AA from phospholipids and its metabolism by 
COX in a manner different from NSAIDs and preventing a 5-LOX shunt of AA metabolism to 
produce  LTs  which  contribute  to  NSAID-induced  side  effects,  flavocoxid  may  allow  for 
preservation of eicosanoid production in extra-articular locations to minimize AEs of the gut, 
kidneys and cardiovascular system. 
 
Flavocoxid  Antioxidant  Mechanism:  Non-enzymatic  lipid  peroxidation  is  another  important 
pathway of AA metabolism. Lipid peroxidation, as a result of poor oxidative status, destabilizes 
cell membranes leading to induction of calcium dependent PLA2 which hydrolytically attacks 
phospholipids leading to the generation of AA [69]. In joints, breakdown of chondrocyte cell 
membranes provides the substrate for PLA2 conversion to AA [70]. When AA is exposed to 
ROS, it is oxidized to F2-isoprostanes, 4-hydroxynonenal (HNE), and malondialdehyde (MDA) Functional Foods in Health and Disease 2012, 2(11):379-413  Page 386 of 413 
[71].  These oxidative AA conversion products are elevated in the synovial fluid, synoviocytes 
and serum of OA patients when compared to healthy control subjects and have been shown to 
stimulate the production of cartilage-degrading matrix metalloproteinases [72, 73]. In addition to 
the  chemical  effects  of  ROS  on  AA  oxidative  products,  ROS  and  cytokines  induce 
transcriptional activation of NFB (Figure 3). 
 
 
Figure 3. Reactive oxygen species (ROS) and cytokine activation of nuclear factor kappa B 
(NFB) pathway of inflammatory gene induction. 
 
Although NFB is essential in normal physiology, inappropriate induction of NFB is part of the 
pathogenesis of arthritis [74, 75]. Radical oxygen species play a major role in signaling the 
production of inflammatory gene expression by activating the nuclear transcription factor NFB 
in  joint  tissue  in  both  RA  and  OA  [76-78].  Nitric  oxide  (NO)  in  particular  induces 
proinflammatory cytokines (i.e., IL-1β, TNFα, IL-6) through NFB activation [79, 80]. NFB 
heterodimers  are  normally  present  in  the  cytoplasm  bound  by  IBα  [81].  Reactive  oxygen 
species and a variety of inflammatory signals bind to integral membrane receptors triggering 
IB kinase which phosphorylates IκBα causing it to dissociate from NFB heterodimer (Figure 
3).  The  controlling  factor  IBα  is  fated  for  digestion  by  the  proteosome.  Activated  NFB 
translocates  to the nucleus  and  binds to  specific  promoter sequences  ahead of inflammatory 
genes called response elements recruiting coactivator proteins and RNA polymerase to transcribe 
the gene into mRNA. The mRNA coding sequence for the inflammatory gene is then translated 
into  proteins,  such  as  cytokines,  COX-2,  5-LOX  and  iNOS  [82,  83]  (Figure  3).  Flavonoid 
molecules have the ability to not only act as antioxidants, but also to directly down-regulate 
NFB activity affecting inflammatory gene and protein expression in joints. 
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  Using a variety of in vitro measures, flavocoxid was shown to have a broad and strong 
antioxidant  profile.  ORAC  analysis  provided  a  measure  of  the  scavenging  capacity  of 
antioxidants against the peroxyl radical, which is one of the most common ROS found in the 
body [84]. The ferric reducing/antioxidant power (FRAP) assay was performed as previously 
described [85]. A validated assay for hydroxyl radical absorbance capacity (HORAC) was also 
performed according described methods [86]. The peroxynitrite radical averting capacity assay 
(NORAC)  and  superoxide  radical  averting  capacity  (SORAC)  assays  were  performed  as 
described previously [87]. Other antioxidant capacity assays used in the analysis of flavocoxid’s 
antioxidant capacity include TEAC (trolox equivalent antioxidant capacity), a method developed 
by Rice-Evans’ group and broadly applied in analyzing food samples [88] and DPPH [2,2-di(4-
tert-octylphenyl)-1-picrylhydroxyl], an easy and accurate method frequently used to measure the 
antioxidant capacity of fruit and vegetable juices and extracts [89]. Based on these analyses, 
flavocoxid neutralized a broad spectrum of oxidative species such as hydroxyl radicals and ions, 
peroxynitrite, nitric oxide and peroxyl radicals (Table 1).  
This broad antioxidant effect may help to explain the fact that flavocoxid significantly 
down-regulated COX-2 gene expression in isolated human peripheral blood monocytes from OA 
patients whereas celecoxib, ibuprofen, and to a minor extent, acetaminophen, augmented COX-2 
gene expression (Figure 4) [From 65].  
 
 
Figure 4.  Eﬀect of ﬂavocoxid versus celecoxib, ibuprofen, and acetominophen on LPS-induced 
COX-1 (gray) and COX-2 (black) gene expression. Human peripheral blood mononuclear cells 
were  isolated  and  co-cultured  with  lipopolysaccharide  (LPS)  at  10  ng/mL  and  3  μg/mL  in 
separate wells of flavocoxid, celecoxib, ibuprofen, or acetaminophen. Total RNAs were prepared 
and cDNAs synthesized. Quantitative PCR assays were run in duplicate primer and probe sets 
for COX-1 and COX-2 genes. Cyclophilin A was used as the reference transcript for the relative 
quantiﬁcation of RNA levels to normalize gene expression [From 65]. 
 
This was a surprising result since both traditional and selective COX-2 NSAIDs bind to and 
inhibit the COX enzyme production of inflammatory AA metabolites. Similar results have been Functional Foods in Health and Disease 2012, 2(11):379-413  Page 388 of 413 
found in patients who experience ulcerations in which COX-2 gene expression is up-regulated 
[90]. While this may be advantageous in maintaining prostaglandin E2 (PGE2) production in the 
upper GI tract to mitigate ulcer formation, COX-2 gene induction could result in greater protein 
production generating elevated PG production associated with increased pain and inflammation. 
More complete gene expression analyses have also been performed with flavocoxid. 
 
Table 1. Antioxidant profile of flavocoxid 
 
 
 
 
 
ORAChydro=Oxygen Radical Absorbance Capacity reflects water-soluble antioxidant capacity; ORAClipo=Oxygen 
Radical Absorbance Capacity lipid-soluble antioxidant capacity; ORACtotal=Combined ORAChydro and ORAClipo; 
HORAC=hydroxyl  radical  absorbance  capacity;  NORAC=  peroxynitrite  radical  averting  capacity; 
SORAC=superoxide radical averting capacity; FRAP=ferric reducing/antioxidant power; TEAC=trolox equivalent 
antioxidant  capacity;  DPPH=2,2-di(4-tert-octylphenyl)-1-picrylhydroxyl  assay;  TE=trolox  equivalents; 
CAE=caffeic acid equivalents; SODeq=superoxide dismutase equivalents [From 65]. 
 
Quantitative PCR (qPCR), microarray analysis and ELISA were used to analyze flavocoxid’s 
effect on inflammatory gene and protein expression [91, 92]. Whether analyzed by qPCR or 
DNA  microarray,  flavocoxid  reduced  lipopolysaccharide  (LPS)-induced  inflammatory  gene 
expression including NFB, IL-1β, TNFα, IL-6 and COX-2 while normalizing gene expression 
for a variety of genes in immortalized human monocytes as well as monocytes isolated from OA 
patients. The induced inflammatory protein levels, as assessed by ELISA, corresponded to the 
effects seen in gene expression assays. In another set of experiments, flavocoxid was shown to 
decrease malondialdehyde, a peroxyl radical product of AA oxidation, in macrophage cultures 
[93].  In  the  same  study,  NFB  activation  and  binding  to  a  model  promoter  sequence  was 
prevented and IBα levels increased suggesting a restoration of NFB regulation (Figure 5). 
This study also showed that flavocoxid-induced down-regulation of mRNA and protein levels of 
TNFα and iNOS as well as decreased protein levels of COX-2 and 5-LOX without effecting 
COX-1 protein expression. As a consequence of decreased COX-2, 5-LOX and iNOS proteins, 
there were decreased levels PGE2, LTB4 and NO (as the stable nitrite marker), respectively [93].  
This MOA data was further demonstrated by Messina et al [94] in a Duchene muscular 
dystrophy (DMD) animal model. Part of the etiology of DMD is induction of inflammatory 
pathways  through  an  oxidative  mechanism.  Currently,  corticosteroids  are  the  only  treatment 
option for DMD patients. In this animal model, flavocoxid: 1) increased forelimb strength; 2) 
normalized strength to weight and decreased fatigue; 3) reduced serum creatine-kinase levels; 4) 
limited the protein expression of oxidative stress markers and of inflammatory mediators COX-
2, 5-LOX and TNFα; 5) inhibited NFB and mitogen-activated protein kinases (MAPKs) signal 
pathways p38 and JunK; 6) reduced muscle necrosis and enhanced regeneration equivalent to 
methylprednisolone. These results suggest that flavocoxid could be used as a therapy in DMD to 
possibly avoid the toxic, long-term side-effects of steroid treatment. A proof-of-principle safety 
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trial is currently underway in Duchene children [95]. Preclinical work has also been performed in 
other disease models on the effect of flavocoxid on oxidatively induced inflammation. 
 
 
 
 
Figure 5. Electrophoretic mobility shift assay (EMSA) of NFB binding activity in the nucleus 
(A) and Western blot analysis of IBα proteins levels (B) in the cytoplasm of macrophages 
stimulated for 1 h with 1 µg/mL of LPS or its vehicle (1 mL of RPMI). Lipopolysaccharide 
(LPS)-stimulated macrophages were co-incubated with ﬂavocoxid (32, 64 and 128 µg/mL) or 
RPMI alone. Bars represent the mean ±SD of seven experiments. *P < 0.05 versus control, 
#P < 
0.01 versus LPS + RPMI, 
##P < 0.005 versus LPS + RPMI, 
§P < 0.001 versus LPS + RPMI 
[From 93]. 
 
In  acute  pancreatitis,  inflammation  triggers  the  expression  of  pancreatic  enzymes  which 
“autocatalytically”  digest  the  pancreas  [96].  This  is  followed  by  massive  infiltration  of 
leukocytes  which  causes  local  and  systemic  inflammatory  responses  often  having  fatal 
consequences.  All  of  these  reactions  are  triggered  by  ROS  damage  and  induction  of 
inflammatory pathways. In an experimental model of acute pancreatitis, Sprague-Dawley rats 
were administered flavocoxid 30 min after injection of caerulein [97]. Flavocoxid acted as a 
rescue therapy inhibiting COX-2 and TNF gene expression as well as 5-LOX activation. In 
addition,  flavocoxid  reduced induced levels  of  PGE2  and  LTB4,  decreased serum lipase and 
amylase levels and protected against the histological damage in terms of cellular vacuolization 
and leukocyte infiltration.  
Inflammation  also  plays  an  important  role  in  the  development  of  benign  prostate 
hyperplasia (BPH). Products derived from the COX and 5-LOX are significantly elevated in the 
enlarging prostate [98, 99]. In rats injected subcutaneously daily with testosterone propionate (3 
mg/kg)  for  14  days  to  induce  BPH,  flavocoxid  reduced  prostate  weight  and  hyperplasia, 
decreased the inducible expression of COX-2 and 5-LOX and, as a consequence, of limiting Functional Foods in Health and Disease 2012, 2(11):379-413  Page 390 of 413 
PGE2 and LTB4 generation, enhanced pro-apoptotic Bax and caspase-9 levels and decreased 
anti-apoptotic  Bcl-2  mRNA  [100].  Flavocoxid  also  reduced  epidermal  growth  factor  and 
vascular  endothelial  growth  factor  expression.  In  human  prostate  carcinoma  PC3  cells, 
flavocoxid-stimulated apoptosis and inhibited growth factor expression.  These data suggest a 
role for flavocoxid-mediated apoptosis during prostatic growth.  
Work has also been performed in a preclinical model of sepsis. In a cecal ligation and 
puncture  (CLP)  model  performed  in  C57BL/6J  mice,  intraperitoneal  injection  of  flavocoxid 
improved survival, reduced the protein expression of NFB, COX-2, 5-LOX, TNFα and IL-6 
and  increased  IL-10  production  [101].  Moreover,  flavocoxid  inhibited  the  mitogen-activated 
protein kinases (MAPKs) pathway, preserved β-arrestin2 expression, significantly reduced blood 
LTB4, PGE2, TNFα and IL-6, and significantly increased anti-inflammatory IL-10 and lipoxin 
A4  serum  levels  compared  to  vehicle.  Finally,  flavocoxid  protected  against  CLP-induced 
histological damage and reduced the myeloperoxidase activity in lung and liver tissue. These 
data suggest that flavocoxid protects mice from the inflammatory consequences of sepsis and 
may represent a promising option for therapy in the future.  
The importance of this antioxidant mechanism cannot be underestimated, especially for the 
management of chronic discomfort which occurs in OA. All the molecules produced from the 
COX-2, 5-LOX and iNOS pathways (e.g., PGs, LTs, and NO) bind to and activate pain receptors 
to cause nociceptive signals that are transmitted to the brain. In addition, cytokines also bind 
these receptors as do a myriad of ROS. Flavocoxid functions to modulate all these pathways to 
affect  inflammation  and pain  perception involved in  OA. The overall  cellular  mechanism is 
represented  in  Figure  7A  showing  that  flavocoxid  acts  broadly  at  many  points  in  the 
inflammatory  cycle  as  opposed  to  NSAIDs  which  principally  act  by  decreasing  eicosanoid 
production (Figure 7B). 
 
Flavocoxid Preclinical Safety and Efficacy: 
Flavocoxid was tested in cell and two rodent models for toxicity before being tested clinically. In 
human immortalized monocytes, flavocoxid yielded no cytotoxicity even at concentrations up to 
100 µg/ml compared to aspirin and celecoxib which induced cell death at 50 and 33 µg/ml, 
respectively [102]. Acute and subchronic animal toxicology data in male and female ICR mice 
showed  a  lack  of  any  harmful  effects  with  human  equivalent  doses  up  to  10  g/day  (acute) 
compared to placebo. There was also no gastric toxicity in Fischer 344 rats, a species sensitive to 
NSAIDs,  as  shown  by  histology  of  the  stomach  mucosa  in  this  study.  Flavocoxid  also 
demonstrated no apparent drug interactions by standard CYP450 enzyme inhibition testing in 
human liver microsomes [102]. There was also no mutagenesis of DNA observed in AMES 
assays. This work in ICR mice and Fischer 344 rats was recently repeated in a more extensive 
animal  toxicology  study  in  Sprague-Dawley  rats  [103].  Yiman  et  al  [103]  demonstrated  no 
flavocoxid-related mortality or ophthalmologic, neurologic (functional observational battery and 
motor  activity),  body  weight,  feed  consumption,  clinical  observation,  organ  weight,  gross 
finding, clinical or histopathological alterations at dose levels of 250, 500, and 1000 mg/kg/day 
(equivalent to 2822, 5645 and 11290 mg per day in a 70 kg human, doses far in excess of those 
given clinically). Normal sperm count and comparable estrus staging were also found for all 
animals tested. A dose of 1000 mg/kg/day was identified as the NOAEL (no-observed adverse-Functional Foods in Health and Disease 2012, 2(11):379-413  Page 391 of 413 
effect-level) in this study. Studies were also performed in animal models to assess the effect of 
flavocoxid in inflammatory models.  
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Figure 7. Broad mechanism of action of flavocoxid (A) versus NSAIDs (B). Flavocoxid acts to 
up-regulate ( + ) elements which damp NFB activation thereby decreasing the expression of 
inducible inflammatory factors such as NFB itself, cytokines, COX-2, 5-LOX and iNOS ( / ). 
Flavocoxid down-regulates or modulates ( - ) specific pathways of inflammation modifying the 
production and conversion of AA to eicosanoids and NO produced by inducible nitric oxide 
synthase  (iNOS).    Prostaglandin  H2  (PGH2),  the  precursor  to  prostaglandin  E2  (PGE2), 
prostacylin (PGI2) and thromboxane (TxA2), is produced through an alternate pathway ( + ). 
NSAIDs work primarily at one point in the COX enzymes, the cyclooxygenase site, inhibiting 
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the production of prostaglandin G2 (PGG2) which results in decreased PGH2 generation ( / ) and 
a consequent reduction in PGE2, PGI2 and TxA2 formation ( / ). 
 
Reductions in ear and ankle swelling induced by AA in animal models were initially used 
to  show  flavocoxid’s  efficacy  in  vivo  [64].  To  determine  if  flavocoxid  had  an  effect  on 
inflammation  in  vivo,  a  validated  mouse  ear  swelling  assay  with  topically  applied  AA  was 
utilized [104]. Twelve hours before applying AA to the back of one ear using the other as an 
internal control, ICR mice were gavaged with either flavocoxid or indomethacin. Microcaliper 
measurements demonstrated that flavocoxid showed an equivalent response in mitigating AA-
induced ear swelling. After confirming the effects of flavocoxid on AA-induced ear swelling, 
AA was injected into the ankle joint of mice previously administered flavocoxid. Flavocoxid 
ameliorated ankle swelling compared to the non-treated animals. In addition, the decrease in 
swelling in ankle joints correlated with improved performance in a walking model on a rotating 
rod [64].   
A  head-to-head  trial  of  a  flavocoxid  formulation  for  animals  against  a  chondroitin 
sulfate/glucosamine hydrochloride/manganese ascorbate formulation (Cosequin
©DS) in canines 
with OA [105] confirmed the superiority of flavocoxid with comparable safety. In this multi-site, 
double-blind,  randomized,  direct-comparator  trial  in  dogs  weighing  at  least  15  lbs  (n=33), 
flavocoxid showed statistically significant improvement in pain scores, almost twice the rate of 
the  chondroitin  sulfate/glucosamine  hydrochloride/manganese  ascorbate  (n=36)  formulation 
using veterinarian and owner visual analog scale (VAS) assessments over a 2-month period. The 
incidence of AEs was low and generally mild in both groups [105].  
Lastly, flavocoxid has been tested in a model of collagen induced arthritis (CIA) for RA. 
When  mice  were  injected  with  collagen  for  21  days  when  and  administered  flavocoxid 
intraperitoneally for 7 days beginning on day 21 after collagen injections, there was a significant 
reduction of serum PGE2 and LTB4 levels as well as systemic  and  synovial fluid  levels  of  
ΤΝFα,  high mobility  group  box  (HMGB)-1  and  IL-6,  while  increasing IL-10 in the joint 
space [106]. Flavocoxid also prevented histological bone erosion in the CIA model decreasing 
the  receptor  activator  of  nuclear  factor-B  ligand  (RANKL)  and  increasing  osteoprotegerin 
(OPG), reducing NFB expression and preventing the loss of the inhibitor of NFB, IBα in the 
joint. 
These results suggest that flavocoxid is able to modulate the inflammatory aspects of joint 
disease  in  preclinical  models.  Though  preclinical,  animal  studies  can  provide  directional 
guidance for development of a product for OA and other disease states, human clinical trials are 
necessary to determine the therapeutic safety and efficacy.  
 
Flavocoxid Clinical Safety and Efficacy: 
A single-dose pharmacokinetic study of 500 mg was given to 10 healthy individuals to determine 
uptake  and  excretion  of  the  baicalin  component  of  flavocoxid  [107].  Although  considerable 
individual variation was noted in the data, the average AUC was 7,007 µg/ml/hour, Cmax was 
0.93 µg/ml, Tmax was 5.8 hours, and the T ½ was approximately 11-12 hours for baicalin. Food 
intake reduced baicalin absorption by about 10%. The half-life for catechin has been reported to 
range from 2 to 3 hours [108] and plasma levels are observed to peak ~3 h after administration in Functional Foods in Health and Disease 2012, 2(11):379-413  Page 393 of 413 
humans, with levels still detectable 120 h later, probably due to reabsorption and enterohepatic 
circulation [109].  
The mechanism of flavocoxid  modulation of  peroxidase activity of the COX enzymes 
would suggest that this agent would not interfere with platelet function. When healthy, human 
volunteers (n=10) took flavocoxid (500 mg BID) for 14 days, there was no significant change in 
either AA-induced or spontaneous platelet aggregation or bleed times compared to baseline [66]. 
Serum  concentrations  of  TxA2  were  unaffected  correlating  with  the  platelet  function  study. 
These  results  suggest  that  flavocoxid  does  not  change  TxA2-induced  platelet  aggregation 
although it inhibits COX-1 peroxidase activity in vitro. Finally, flavocoxid did not inhibit or 
potentiate the anti-coagulant effect of warfarin, as measured by INR, in previously warfarinized 
OA patients at either 250 or 500 mg BID after 14 days of dosing (n=59) [66].  In the same 
manuscript,  a  preclinical  model  of  aspirin-induced  bleeding  showed  that  flavocoxid  neither 
augmented or inhibited bleed times in combination with aspirin or alone. Additional safety and 
efficacy studies in OA subjects have also recently been performed. 
In  an  8-week  randomized,  placebo-controlled  human  clinical  trial  (n=80),  flavocoxid 
administered to  healthy  volunteers at  250 mg QD demonstrated an equivalent, mild  adverse 
event  (AE)  profile  to  placebo,  with  no  changes  in  serology  or  blood  chemistry  in  healthy 
individuals  [102]. Morgan et  al  [110] enrolled  subjects  (n=59)  with  moderate to  severe  OA 
[Kellgren-Lawrence  (K-L)  2-3  scores]  and  “below  average”  to  “moderately  above  average 
cardiovascular risk” subjects as judged by Framingham Criteria to examine the effects of 250 mg 
BID of flavocoxid in a randomized, placebo-controlled single-site study for 12 weeks. After 12 
weeks,  there  were  no  changes  in  blood  chemistries,  but  flavocoxid  showed  a  significantly 
reduced number of upper respiratory AEs (p<0.0003) compared to placebo suggesting and anti-
infective and anti-leukotriene effect. Both baicalin and catechin have anti-viral and antibacterial 
activities against a variety of pathogens and are used for this purpose as approved drugs in Asia 
[111-115]. The significant reduction in upper respiratory AEs may also suggest a beneficial role 
for 5-LOX inhibition in modulating vasoconstrictive LTs in the upper airways. There were also 
no differing anxiolytic effects in the two groups in the study. After showing an acceptable safety 
profile in both animals and humans at lower doses, flavocoxid was then tested for safety and 
efficacy at 500 mg BID. 
Levy et al [116] showed that when flavocoxid was administered at 500 mg BID versus 500 
mg BID naproxen during a 4-week, double-blind prospective short-term acute therapy study 
(n=103) in moderate to severe OA subjects (K-L 2-3 scores), it showed equivalent efficacy to 
naproxen  as  measured  by  the  short  Western  Ontario  and  McMaster  Osteoarthritis  Index 
(WOMAC) as well as by patient and physician visual analogue scale (VAS) scores (Table 2) 
[From 116]. Adverse events were mild and roughly equivalent in both arms of this short-term 
efficacy study. The trial was not powered sufficiently to judge safety. Therefore, a longer and  
larger trial was performed in patients with OA of the knee using validated measures to assess 
long-term safety and efficacy.  
This study was a randomized, multi-center, double-blind study in which 220 subjects who 
had been on previous NSAID therapy using a flare design after washout were administered either 
flavocoxid (500 mg BID) or naproxen (500 mg BID) to measure long-term safety and efficacy 
over a 12-week period [117]. Outcome measures included WOMAC, timed walk, investigator Functional Foods in Health and Disease 2012, 2(11):379-413  Page 394 of 413 
and subject measures for disease activity, global response to therapy assessed by investigator and 
subject and subject VASs for discomfort, overall disease activity and index joint tenderness and 
mobility. More than 90% of the subjects in both groups noted significant reduction in the signs 
and symptoms of knee OA with no statistically significant differences in efficacy between the 
flavocoxid and naproxen groups when the entire intent to treat population was analyzed for any 
parameter (Table 3). Trends toward significance were noted in 6 out of 7 efficacy measures for 
flavocoxid  over naproxen between 6 and 12 weeks,  with  subject  global response to  therapy 
(SGRT) being the only exception.  
 
Table  2.  Improvement  in  Western  Ontario  and  McMaster  University  Index  (WOMAC)  and 
visual analogue scale (VAS) 
 
Western  Ontario  and  McMaster  University  Osteoarthritis  Index  (WOMAC),  Physician  Global  Assessment  of 
Disease Visual Analogue Scale (PGAD), Subject Global Assessment of Disease Visual Analogue Scale (SGAD), 
Subject Global Assessment of Discomfort Visual Analogue Scale (SGADc) [From 116].  
 
Trends for efficacy observed in the formal, long-term safety and efficacy trial [117] between 6 
and 12 weeks initiated further investigation into the subpopulation effects of flavocoxid. When 
the subjects below the mean for the investigator global assessment of disease (IGAD <8) were 
analyzed for the WOMAC composite index and its subscales, flavocoxid showed statistically 
better scores at 6 and 12 weeks for the WOMAC index and the subscales of pain and physical 
function suggesting moderate OA subjects respond better to flavocoxid than to naproxen [118]. 
Further subanalysis of subjects with walking times less than 14 seconds showed that flavocoxid 
seemed to become more efficacious compared to naproxen with p values improving between 6 
and 12 weeks. The reason for the longer onset of action and continued improvement may be due 
to the pharmacodynamics of flavonoid binding to and absorption into red blood cells which 
requires saturation before full efficacy may be attained [119].  
In terms of safety, flavocoxid exhibited significantly fewer upper GI and renal (edema) 
AEs [117]. Over 12-weeks, there was a mean increase of 0.015 mg/dL in serum creatinine in the 
naproxen arm and a mean decrease of 0.018 mg/dL in the flavocoxid arm (P=0.18) suggesting a 
possible trend toward less renal toxicity with flavocoxid. Twenty-four subjects had elevations of 
hepatic  transaminase  enzymes  greater  than  1.2  the  upper  limit  of  normal  at  screening  (13 
flavocoxid;  11  naproxen).  At  12  weeks,  approximately  half  of  these  had  normalized  (7 
flavocoxid; 5 naproxen). Conversely, there were 16 subjects whose transaminases were normal at 
screening  and  elevated  at  12  weeks  (11  flavocoxid;  5  naproxen  [p=0.087]).  There  were  12 
elevations  of  total  bilirubin  between  screening  and  12  weeks  (5  flavocoxid;  7  naproxen 
[p=0.18]). There were only 2 subjects with elevated alkaline phosphatase at screening, one in 
each  group.  Almost  all  of  the  abnormalities  for  hepatic  transaminases  and  bilirubin  in  both Functional Foods in Health and Disease 2012, 2(11):379-413  Page 395 of 413 
groups were within 1.5-3 times upper limit of normal for the reference laboratory and none 
exceeded 5-times the upper limit of normal [117]. Because of the fluctuating numbers of minor 
transaminase abnormalities, it is unclear if these data are related to study products or due to 
environmental or cultural phenomena. 
 
Table 3. Summary of efficacy parameters outcomes for flavocoxid and naproxen at 6 and 12 
weeks [From 117] 
 
Post-marketing surveillance tracked for more than 8 years of marketing Limbrel (flavocoxid) in 
the US and Puerto Rico has found a low incidence of reported elevated liver function tests (LFT) 
(40 events out of almost 325,000 patients or 0.012%) [120]. Most of these LFTs were 1-3x’s the 
upper limit of normal, but a few notable cases were severe hepatic reactions accompanied by 
jaundice, some with  eosinophilia suggesting an allergic basis. All abnormal LFT appeared in the 
first  three  months  of  flavocoxid  administration  and  all  resolved  without  residua  after 
discontinuing flavocoxid. By comparison, the incidence of post-marketing reports of LFTs for 
NSAIDS is between 2.7% and 3% worldwide [121]. 
In  a  recent  case  study  from  a  registry  of  877  individuals  drug  induced  liver  injury 
accumulated  over  a  6  year  period  with  3  patients  in  the  registry  had  liver  injury  linked  to Functional Foods in Health and Disease 2012, 2(11):379-413  Page 396 of 413 
flavocoxid use with one patient possibly linked to use of the product [122]. Abnormal  LFT 
appeared  1  to  3  months  after  beginning  flavocoxid  therapy  in  the  individuals  which  were 
identified. After discontinuing flavocoxid,  all patients  fully recovered  without residua unlike 
other anti-inflammatory agents which have been shown to cause liver failure, in some cases 
requiring  liver  transplantation  [123,  124].  As  shown  above  in  a  head-to-head  clinical  trial, 
flavocoxid had the same incidence of LFT as naproxen. All LFTs appear to be idiosyncratic with 
no known causality. Therefore, it is recommended that liver function be tested two months after 
initiating therapy on flavocoxid and then thereafter as per usual practice of the physician. 
Hypersensitivity pneumonitis is the only other serious AE that has been reported in post-
marketing surveillance for flavocoxid. To date, there have been 12 confirmed and 5 unconfirmed 
cases of this event in post-marketing surveillance [120]. These have occurred in patients with no 
prior history of allergic or pulmonary disease or other predictive factors and appear to be entirely 
idiosyncratic. Youssef and Tomic [125] noted a single case of “bibasilar infiltrates and CT chest 
confirmed bilateral lower lobe consolidation” in a 64-year old female patient. The pneumonitis 
resolved with oxygen administration, corticosteroids and discontinuation of flavocoxid without 
residua.  These  serious  AEs  have  been  reported  to  the  US  Food  and  Drug  Administration 
MedWatch [126]. 
It is always helpful to assess safety and efficacy in a real world clinical setting. A post-
marketing,  phase  IV-like  study  of  flavocoxid  at  500  mg  BID  (n=1067)  conducted  in  41 
rheumatology practices across the U.S. over a 2-month period was performed in moderate to 
severe  OA  patients  (K-L  2-3  scores)  [127].  There  was  significant  improvement  in  66%  of 
patients using physician administered VAS pain scales. The strongest efficacy was noted in those 
patients with moderate to severe OA (Figure 6A), in those patients who were non-responders to 
previous NSAIDs for OA (Figure 6B) and in males.  
Out  of  1067  individuals  initially  enrolled  in  the  study,  1005  persons  completed  all 
scheduled visits. Six dropped out because of an AE [bladder burning (1), sour stomach (1), 
increased pain (1), severe diarrhea (1), and unspecified (2)] while 56 individuals were lost to 
follow-up. Drop-out rates were much lower (0.6%) compared to a similar post-marketing studies 
of diclofenac (18%) and celecoxib (13% total withdrawals with 4% withdrawing due to GI AEs) 
[128,  129].  A  low  incidence  of  AEs  (~10%)  and  good  overall  tolerability  of  patients  to 
flavocoxid was noted in this tightly monitored study. The use of flavocoxid also improved upper 
GI  tolerability  in  almost  50%  of  previous  NSAID-intolerant  users  and  reduced  therapy 
interruption  in  90%  of  participants  with  a  history  of  NSAID-induced,  GI-related  therapy 
interruptions.  Importantly,  the  use  of  proton  pump  inhibitors  (PPIs)  or  histamine-2  receptor 
blockers (H2s) decreased or ceased by over 30% in patients who previously required them in 
order to tolerate their prior NSAID therapy.   
The clinical trials and phase-IV study cited above, in addition to national rheumatologist 
opinion, and literature comparisons were utilized to perform a pharmacoeconomic analysis. This 
analysis demonstrated that the cost of care, using a “one year window of treatment” decision 
model to estimate the total costs associated with use of flavocoxid or naproxen for patients with 
mild to moderate OA over age 65, that Limbrel (flavocoxid) was lower in the flavocoxid treated 
patients  in  the  first  year  of  therapy  [130].  Thus,  even  though  generic  NSAIDs  may  have  a 
cheaper initial cost, when the cost of gastroprotective medications and side effect treatment, Functional Foods in Health and Disease 2012, 2(11):379-413  Page 397 of 413 
including hospitalizations for upper GI events are taken into account, flavocoxid is the safer and 
less expensive option. 
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Figure  6.  Percent  improvement  in  Physician  Global  Assessment  of  Disease  (PGAD)  visual 
analog scales (VAS)-stratified by baseline OA severity in patients administered 500 mg BID 
Limbrel
  for  8  weeks.  All  between-group  differences  and  each  group’s  improvement  over 
baseline was significant, p<0.001 (A).  Percent improvement in PGAD VAS-based on baseline 
NSAID use and response to this prior use in patients administered 500 mg BID Limbrel
 for 8 
weeks. All groups also reported a significant improvement over baseline, p<0.001 (B) [From 
127]. 
 
Finally, a recent case study report suggested how Limbrel can be used in patients with 
drug  failures  and  toxicities  while  on  traditional  NSAIDs  and  in  those  with  cardiovascular 
comorbidity associated with the utilization of selective COX-2 inhibitors [131]. A 66-year old 
female with congestive heart failure on an angiotensin-converting enzyme (ACE) inhibitor, a 
beta blocker, and thiazide diuretic also having type 2 diabetes mellitus treated with metformin 
and sulfonylurea and mild renal insufficiency and who had a GI ulceration due to naproxen as 
well as mild hypertension was  administered 500 mg BID of flavocoxid for three months.  She 
noted a decrease in dyspepsia and her blood pressure dropped from 142/92 to 134/84. Her OA Functional Foods in Health and Disease 2012, 2(11):379-413  Page 398 of 413 
symptoms  and  edema  improved  over  the  three  months  of  therapy  suggesting  the  utility  of 
flavocoxid in this fragile patient type. 
 
Other Nutritional Molecules/Formulations: 
Nutritional intervention in the form of medical foods, functional foods and dietary supplements 
is more commonplace due to patient perception and reported side effects of current NSAIDs. A 
number of nutritional molecules have been tested in clinical trials for OA. Pycnogenol
 is a 
mixture of procyanidins, flavonoids and organic acids extracted from French maritime pine bark 
[132]. Curcumin has been complexed with soy derived phosphatidylcholine (Meriva
) to create a 
more bioavailable form of the molecule [133]. Another bioavailable form of curcumin, BCM-
95
®  CG  (Biocurcumax™),  contains  curcumoids  as  well  as  tumerone  oil  co-purified  from 
Curcuma longa [134]. Three different forms of boswellic acid exist from  Boswellia serrata, 
BosPure
 a 10% or more purity 3-O-acetyl-keto-11-beta-boswellic acid (AKBA) and very low 
β-boswellic acid (<5%) extract, 5-Loxin
, a 30% AKBA containing extract [135] and Aflapin
 a 
30% AKBA containing extract with B. serrata non-volatile oils [144]. Sterol-rich fractions of 
avocado soybean unsaponifiables (ASU) have been isolated as early has the 1970’s for use in 
clinical  medicine  [136].  A  comparison  of  different  nutritional  molecules  used  in  safety  and 
efficacy OA trials are listed in Table 4.  
 
Table 4. Clinical studies of nutritional molecules in osteoarthritis 
Reference  Type of Study  Intervention  Participants 
Follow-up and 
Assessment(s) 
Major Safety and Efficacy 
Outcome(s) 
Flavocoxid 
(Limbrel
) 
         
102  RCT, double-
blind, placebo 
controlled 
safety 
250 mg QD 
of Limbrel vs 
placebo 
80 healthy 
subjects 
8 week study, 
assessments at 
baseline and 8 
weeks 
Mild AE profile similar to placebo, 
No changes in serology or blood 
chemistry in either group 
110  RCT, double-
blind, placebo-
controlled 
safety 
250 mg BID 
Limbrel
 vs 
placebo BID 
59 subjects, 
moderate to 
severe OA 
(K-L=2-3),  
below 
average to 
moderately 
above average 
CV risk 
12 week study, 
assessments at 
baseline, 2, 4, 
8, and 12 
weeks 
No differences in blood chemistries, 
Significantly reduced upper 
respiratory AEs for flavocoxid vs 
placebo (p<0.0003), No differences 
in depression or anxiety scores 
116  RCT, double-
blind, direct 
comparator to 
naproxen for 
efficacy 
500 mg BID 
Limbrel
 vs 
500 mg BID 
naproxen 
103 subjects, 
moderate to 
severe OA 
(K-L=2-3) 
4 week study, 
assessments at 
baseline and 4 
weeks 
Equivalent AEs, Equivalent short 
WOMAC, subject/physician VAS 
scores 
117, 118  RCT, double-
blind, direct 
comparator to 
naproxen for 
safety and 
efficacy 
500 mg BID 
Limbrel
 vs 
500 mg BID 
naproxen 
220 subjects, 
moderate to 
severe OA 
(K-L=2-3) 
12 week study, 
assessments at 
baseline, 6 and 
12 weeks 
Statistically better upper GI 
(dyspepsia) and renal (edema) AE 
profile for flavocoxid vs naproxen, 
Statistically more flatulence for 
flavocoxid vs naproxen, Equivalent 
WOMAC composite and subscale 
scores as well as various 
subject/physician VAS scores and Functional Foods in Health and Disease 2012, 2(11):379-413  Page 399 of 413 
timed walk in the entire intent to 
treat population, Statistically better 
WOMAC composite, pain and 
physical function subscales as well 
as various subject/physician VAS 
scores and timed walk of flavocoxid 
vs naproxen in moderate OA 
subjects 
127  Open-Label, 
Phase IV Post-
marketing, 
safety with 
physician 
judged efficacy 
500 mg BID 
Limbrel
 
1067 patients 
with moderate 
to severe OA 
(K-L=2-3) 
8 week study, 
assessments at 
baseline and 8 
weeks 
~10% AE rate, 31% reduction in 
gastroprotective use, 48% greater GI 
tolerance in patients previously with 
GI problems with NSAIDs, 
Statistically better pain response 
rates in patients who had no 
previously responded to NSAID 
therapy and in patients with the 
highest baseline VAS scores 
131  Open-Label, 
Case Study, 
safety with 
physician and 
patient judged 
efficacy 
500 mg BID 
Limbrel
 
1 patient with 
severe OA, 
congestive 
heart failure, 
mild 
hypertension, 
type 2 
diabetes 
mellitus, mild 
renal 
insufficiency, 
and a 
previous GI 
ulcers on 
NSAIDs 
3 month 
follow-up by 
physician 
The patient showed a drop in blood 
pressure toward normal, improved 
edema and returned to her exercise 
routine. There were no other 
complaints while on Limbrel. 
Pycnogenol
           
137  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy 
150 mg QD 
Pycnogenol 
100 subjects 
with mild to 
moderate OA 
(K-L=1-2) 
3 month study, 
assessments at 
clinic at 
baseline, 4, 8 
and 12 weeks 
of therapy with 
a 4 week post-
intervention 
assessment, 
weekly VAS 
pain scale  and 
biweekly 
WOMAC 
composite 
index and 
subscales by 
subjects 
Statistically significant 
improvement for WOMAC 
composite index and its subscales by 
8 weeks for Pycnogenol vs 
placebo, No statistical difference in 
VAS scores or AEs, Trend for 
decreased rescue analgesic use in the 
Pycnogenol vs placebo group 
138  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy 
100 mg QD  145 subjects 
with mild to 
moderate OA 
(K-L=1-2) 
3 month study, 
assessments at 
baseline and 3 
months 
Statistically significant 
improvement for WOMAC 
composite index for Pycnogenol 
vs placebo, Statistical improvement 
in edema for for Pycnogenol vs 
placebo, Statistical reduction in Functional Foods in Health and Disease 2012, 2(11):379-413  Page 400 of 413 
rescue analgesic use in the for 
Pycnogenol vs placebo group 
Curcumin 
(Meriva
) 
         
139  Open-label, 
placebo 
comparison 
recruited from 
registry of 
patients with 
vascular 
disease for 
efficacy 
1 g QD 
Meriva
 (200 
mg curcumin) 
50 patients 
with mild to 
moderate OA 
(K-L=1-2) 
3 month study, 
assessments at 
baseline, 2 and 
3 months 
Statistically significant 
improvement of WOMAC 
composite index for Meriva
 plus 
standard of care vs standard of care 
alone at 3 months, Significantly 
better physical performance in 
walking on treadmill at 2 and 3 
months for Meriva
 plus standard of 
care vs standard of care alone, 
Significant reduction in CRP in 
Meriva
 plus standard of care vs 
standard of care alone at 2 months, 
Decreased cost of treatment (rescue 
analgesics, treatment, 
hospitalization) in Meriva
 plus 
standard of care vs standard of care 
alone, No difference between 
Meriva
 plus standard of care vs 
standard of care alone in social or 
emotional function scores 
140  Open-label, 
placebo 
comparison 
recruited from 
registry of 
patients with 
vascular 
disease for 
efficacy 
500 mg BID 
Meriva
 (200 
mg curcumin) 
100 patients 
with mild to 
moderate OA 
(K-L=1-2) 
8 month study, 
assessments at 
baseline and 8 
months 
Statistically significant 
improvement for WOMAC 
composite index and subscales of 
pain, stiffness and physical function 
for Meriva
 plus standard of care vs 
standard of care alone, Significant 
improvement in social and 
emotional function for Meriva
 plus 
standard of care vs standard of care 
alone, Significantly better physical 
performance in walking on treadmill 
for Meriva
 plus standard of care vs 
standard of care alone, Significantly 
improved levels of the markers 
sCD40L, IL-1b, IL-6, sVCAM-1, 
and ESR for Meriva
 plus standard 
of care vs standard of care 
BCM-95
           
141  RCT, double-
blind, direct 
comparator to 
celecoxib for 
safety and 
efficacy 
500 mg BID 
BCM-95
 
with 
BosPure
 
(Rhulief™) vs 
100 mg BID 
celecoxib 
30 subjects 
diagnosed 
with OA of 
the knee, 
unknown 
severity 
12 week study, 
assessments at 
baseline and 12 
weeks 
Equivalent pain scores, walking 
distance and range of motion 
between groups, Both groups 
showed statistical improvement over 
baseline, Equivalent AEs 
5-Loxin
           
142  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy 
100 mg QD 
and 250 mg 
QD 5-Loxin
 
vs placebo 
75 subjects 
with mild to 
moderate OA 
(According to 
baseline VAS 
scoring) 
90 day study, 
assessments at 
baseline, 7, 30, 
60 and 90 days 
Both doses of 5-Loxin
 showed 
statistically significant 
improvements in VAS, WOMAC 
composite index and subscale scores 
for pain, stiffness and physical 
function as well as scores for the Functional Foods in Health and Disease 2012, 2(11):379-413  Page 401 of 413 
Lequesne’s Functional Index [143] 
vs placebo starting at 7 days for the 
high dose, the 5-Loxin
 also showed 
statistically decreased levels of 
metalloproteinase-3 (MMP-3) from 
synovial fluid compared to placebo, 
AEs were comparable in all groups 
144  RCT, double-
blind, 
comparator, 
placebo-
controlled 
safety and 
efficacy 
100 mg QD 
5-Loxin
 vs 
100 mg QD  
Aflapin
 vs 
placebo 
60 subjects 
with 
mild to 
moderate OA 
(According to 
baseline VAS 
scoring) 
90 day study, 
assessments at 
baseline, 7, 30, 
60 and 90 days 
Both 5-Loxin
 and Aflapin
 
showed statistically significant 
improvements in VAS, WOMAC 
composite index and subscale scores 
for pain, stiffness and physical 
function as well as scores for the 
Lequesne’s Functional Index [143] 
vs placebo, Onset of action was 
quicker for Aflapin, AEs were 
comparable in all groups 
Avocado/Soy
bean 
Unsaponifi-
ables (ASU) 
         
145  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy, added 
on to NSAID 
therapy 
300 mg QD 
ASU vs 
placebo 
 
164 subjects 
with mild to 
moderate OA 
(K-L=1-3), 
using 
NSAIDs 
3 month study, 
assessments at 
baseline, 45 
and 90 days, 
NSAID co-
administered 
for first 45 
days, reduction 
in NSAID use 
measured 
thereafter 
Statistical reduction in NSAID use 
in ASU group vs placebo, Global 
quality of life scores statistically 
better in ASU vs placebo, No 
difference in pain scores, 
Comparable AEs in both groups 
146  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy, added 
on to NSAID 
therapy 
300 mg and 
600 mg QD 
ASU vs 
placebo 
260 subjects 
with mild to 
moderate OA  
(K-L=1-3), 
using 
NSAIDs 
3 month study, 
assessments at 
baseline, 30, 60 
and 90 days, 
NSAID co-
administered 
for first 30 
days, reduction 
in NSAID use 
measured 
thereafter 
Statistical reduction in NSAID in 
ASU group vs placebo, Significantly 
better Lequesne’s Functional Index 
[143]  and pain scores in ASU 
groups vs placebo, Global quality of 
life scores statistically better in ASU 
groups vs placebo, Comparable AEs 
in all groups 
147  RCT, double-
blind, placebo-
controlled 
safety and 
efficacy, added 
on to NSAID 
therapy 
300 mg QD 
ASU vs 
placebo 
164 subjects 
with mild to 
moderate OA 
(K-L=1-3), 
using 
NSAIDs 
8 month study 
with a 2 month 
follow up, 
NSAIDs 
withdrawn 15 
days prior to 
start of trial 
and then 
allowed as 
rescue 
medication 
Statistical improvement Lequesne’s 
Functional Index [143]  and pain 
scores in ASU group vs placebo, 
Significantly better functional 
ability and global quality of life 
scores in ASU vs placebo, Non-
statistical reduction in NSAID use in 
ASU group vs placebo, 
Improvements in functional and 
quality of life scores continued 2 
months after discontinuation vs 
placebo, Comparable AEs in both 
groups 
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Randomized Controlled Trial (RCT), Western Ontario and McMaster University Osteoarthritis Index (WOMAC), 
Twice daily (BID), Osteoarthritis (OA), Adverse Events (AEs), Gastrointestinal (GI), Kellgren-Lawrence (K-L), 
Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Visual Analogue Scale (VAS), Soluble CD40 ligand (sCD40L), 
Interleukin 1beta (IL-1β), Interleukin 6 ( IL-6), Soluble vascular cell adhesion molecule-1 (VCAM-1), Erythrocyte 
Sedimentation Rate (ESR), Avocado Soybean Unsaponifiables (ASU) 
 
Lastly, the intake of glucosamine and chondroitin is controversial and beyond the scope of this 
review. Some clinical studies [148-150] and meta-analyses [151] suggest effectiveness in OA 
while other meta-analyses contradict these data [152, 153]. 
 
CONCLUSION: 
Flavocoxid is arguably one of the better studied nutritional therapies for OA with a history of use 
in  the  US  since  2004.  Though  reasonable  and  promising  data  exist  for  other  nutritional 
interventions,  consistency  of  formulation  and  mixtures  with  other  agents  make  their  choice 
difficult  to  recommend  by  physicians  and  confusing  to  consumers.  Since  medical  foods  are 
assessed for GRAS by expert panel review of animal and human toxicology, have known and 
FDA-auditable quantities of specific nutrients as well as a requirement they be produced under 
GMPs, have clear instructions of use in the form of package inserts which must document their 
claims of safety and efficacy and are required to be dosed and monitored by physicians to assure 
their safe use, flavocoxid represents a safe and reasonable option for patients with OA who have 
shown toxicities to NSAIDs or have co-morbidities which require polypharmacy. Additional 
studies in special populations such as renal insufficient individuals and patients with a history of 
GI ulceration are needed to verify flavocoxid’s safety profile. In addition, larger, future studies in 
OA of the knee, hip  and hand will further expand the knowledge and use of flavocoxid  in 
patients with chronic joint disease. 
 
List of Abbreviations: 
5-LOX-5-lipoxygenase,  AA-arachidonic  acid,  ACE-angiotensin-converting  enzyme  inhibitor, 
AE-adverse event, ASU-avocado soybean unsaponifiables, BID twice daily, CLP-cecal ligation 
and  puncture,  COX-cyclooxygenase,  CIA-collagen-induced  arthritis,  CRP-C-reactive  protein, 
DMD-Duchene  muscular  dystrophy,  DPPH-2,2-di(4-tert-octylphenyl)-1-picrylhydroxyl,  ESR-
erythrocyte  sedimentation  rate,  FRAP-ferric  reducing/antioxidant  power,  GRAS-  generally 
recognized as safe, GI-gastrointestinal, GMPs-good manufacturing practices, H2s-histamine-2 
receptor  blockers,  HNE-  4-hydroxynonenal,  HORAC-hydroxyl  radical  absorbance  capacity, 
IGRT-Investigator Global Response to Therapy, IL-1β-Interleukin-1β, IL-6-Interleukin 6, IL-10-
Interleukin 10, HMGB-1- high mobility  group  box, iNOS-inducible nitric oxide synthase, INR-
international  normalized  ratio,  Kellgren-Lawrence-K-L,  LFT-liver  function  tests,  LT-
Leukotriene,  MAPKs-mitogen-activated  protein  kinases,  MDA-malondialdehyde,  MMP-3-
metalloproteinase-3,  MOA-mechanism  of  action,  NFB-nuclear  factor  kappa  B,  NO-Nitric 
oxide,  NOAEL-no-observed  adverse-effect-level,  NSAIDs-nonsteroidal  anti-inflammatory 
drugs,  OA-osteoarthritis,  PGAD-Physician  Global  Assessment  of  Disease  Visual  Analogue 
Scale,  PGE2-prostaglandin  E2,  PGG2-prostaglandin  G2,  PGH2-prostaglandin  H2,  PGI2- 
prostacyclin, PGs-Prostaglandins, PLA2-Phospholipase A2, PPIs-proton pump inhibitors, RA-
rheumatoid  arthritis,  RANKL-receptor  activator  of  nuclear  factor-B  ligand,  SGAD-Subject Functional Foods in Health and Disease 2012, 2(11):379-413  Page 403 of 413 
Global Assessment of Disease Visual Analogue Scale, SGADc-Subject Global Assessment of 
Discomfort  Visual  Analogue  Scale, SGRT-Subject  Global  Response  to  Therapy,  sVCAM-1-
soluble vascular cell adhesion molecule, SORAC-superoxide radical averting capacity, TEAC-
trolox equivalent antioxidant capacity, TNFα-Tumor necrosis factor-alpha, TxA2-Thromboxane, 
VAS-visual  analogue  scale,  WOMAC-Western  Ontario  and  McMaster  Osteoarthritis  Index, 
RCT-randomized, placebo-controlled trial 
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